Gilde Healthcare Services invests in nursing homes - Gilde Healthcare

Gilde Healthcare Services invests in nursing homes

October 25, 2010

Utrecht, The Netherlands – Gilde Healthcare Services (Gilde), a growth capital fund specialised in Healthcare Services, has acquired a significant minority stake in elderly care provider Stepping Stones Home & Care (Stepping Stones) of the Netherlands to fund further growth of the company.

Stepping Stones operates a chain of nursing homes providing care for elderly with Alzheimer’s disease and related conditions that need continuous support. The nursing homes offer a safe, protected and continuous care environment with affordable services tailored to the needs of residents (www.steppingstonesbv.nl).

Stepping Stones founding managers Arthur Scherpenzeel and Christiaan Sap commented:

“We are thrilled with the investment from Gilde. This investment not only enables us to expand the number of locations but we will also benefit from Gilde’s hands-on approach and healthcare expertise.

Jasper van Gorp, Partner of the Gilde Healthcare Services fund said:

“We were impressed by Stepping Stones’ ability to provide a very high quality yet affordable care home service. We believe that there is a considerable need for this type of service which can co-exist alongside care provided by the public sector in the Netherlands. This investment is aligned perfectly with our investment focus on high growth healthcare services companies.

Gilde Healthcare company Tagworks Pharmaceuticals Announces FDA Clearance of IND Application and Initiation of Phase 1 Clinical Trial for TGW101

TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which enables superior control of...
April 22, 2025

Gilde Healthcare company SynOx Therapeutics announces Board Chair transition to align with advancing Regulatory and Commercialization Strategy

SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced the execution of a planned and orderly transition of its board chair position. Philip Astley-Sparke...
April 1, 2025

Gilde Healthcare company SpliceBio announces first patient dosed in Phase 1/2 ASTRA study of SB-007, a Dual-AAV Gene Therapy for Stargardt Disease

SB-007 addresses the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations SB-007 is the first dual AAV gene therapy in clinical development for Stargardt disease   SpliceBio,...
March 13, 2025